Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?
Lakewood-Amedex Biotherapeutics stock rallied on Monday after it announced new data for its lead candidate.
Lakewood-Amedex Biotherapeutics Inc. (LABT)
Market is closed
News See All
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company’s evolution Strengthened balance sheet...
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Sarasota, Florida - Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials...
Hedge Fund Resource Center